These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 25480887)

  • 1. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
    Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
    Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
    Wratten S; Abetz-Webb L; Arenson E; Griffiths P; Bowman S; Hueber W; Ndife B; Kuessner D; Goswami P
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36931685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
    Lendrem D; Mitchell S; McMeekin P; Gompels L; Hackett K; Bowman S; Price E; Pease CT; Emery P; Andrews J; Lanyon P; Hunter J; Gupta M; Bombardieri M; Sutcliffe N; Pitzalis C; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Griffiths B; Ng WF;
    Rheumatology (Oxford); 2015 Apr; 54(4):655-9. PubMed ID: 25240612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sleep quality on clinical features of primary Sjögren's syndrome.
    Chung SW; Hur J; Ha YJ; Kang EH; Hyon JY; Lee HJ; Song YW; Lee YJ
    Korean J Intern Med; 2019 Sep; 34(5):1154-1164. PubMed ID: 29458245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
    PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and adaptation to Spanish of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
    Posso-Osorio I; Nieto-Aristizábal I; Soto D; Ariza C; Urbano M; Cañas CA; Echeverri A; Castillo A; Tobón GJ
    Reumatol Clin (Engl Ed); 2021; 17(7):388-391. PubMed ID: 34301381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
    Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
    Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
    Cho HJ; Yoo JJ; Yun CY; Kang EH; Lee HJ; Hyon JY; Song YW; Lee YJ
    Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.
    Seror R; Mariette X; Bowman S; Baron G; Gottenberg JE; Bootsma H; Theander E; Tzioufas A; Vitali C; Ravaud P;
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):551-8. PubMed ID: 20391511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA; Mariette X; Papas A; Grader-Beck T; Bootsma H; Ng WF; van Daele PLA; Finzel S; Noaiseh G; Elgueta S; Hermann J; McCoy SS; Akpek E; Bookman A; Sopala M; Montecchi-Palmer M; Luo WL; Scheurer C; Hueber W;
    Lancet; 2024 Aug; 404(10452):540-553. PubMed ID: 39096929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.